Name: PharmAthene Inc.
Big idea: Developing countermeasures for bioterrorism, including treatments and vaccines for anthrax and other chemical toxins.
Web site: www.pharmathene.com
Who's in charge: David P. Wright, president and chief executive
Funding: PharmAthene received $13 million in seed money from the Defense Advanced Research Projects Agency (DARPA), raised $15 million in a first round from HealthCare Ventures, and raised $50 million in a second round from MPM Capital, Bear Stearns Health Innoventures and HealthCare Ventures.
Employees: 15. The company will add 56 employees when it completes its acquisition of Nexia Biotechnologies Inc.
Partners: PharmAthene is collaborating with Medarex Inc. to develop a monoclonal antibody called Valortim. The company has a relationships with DARPA, the Army Medical Research Institute of Infectious Disease, the University of Wisconsin's Alumni Research Foundation and the Salk Institute in San Diego. The company is also in a research collaboration partnership with the University of Maryland.
Origin of company name: "Athena is the goddess of warfare and the protectorate, so it's pharmaceutical protection against warfare," Wright said.